The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention

Sarah L. Kerns, Suman Kundu, Jung Hun Oh, Sandeep K. Singhal, Michelle Janelsins, Lois B. Travis, Joseph O. Deasy, A. Cecile J E Janssens, Harry Ostrer, Matthew Parliament, Nawaid Usmani, Barry S. Rosenstein

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Radiotherapy is a mainstay of cancer treatment, used in either a curative or palliative manner to treat approximately 50% of patients with cancer. Normal tissue toxicity limits the doses used in standard radiation therapy protocols and impedes improvements in radiotherapy efficacy. Damage to surrounding normal tissues can produce reactions ranging from bothersome symptoms that negatively affect quality of life to severe life-threatening complications. Improved ways of predicting, before treatment, the risk for development of normal tissue toxicity may allow for more personalized treatment and reduce the incidence and severity of late effects. There is increasing recognition that the cause of normal tissue toxicity is multifactorial and includes genetic factors in addition to radiation dose and volume of exposure, underlying comorbidities, age, concomitant chemotherapy or hormonal therapy, and use of other medications. An understanding of the specific genetic risk factors for normal tissue response to radiation has the potential to enhance our ability to predict adverse outcomes at the treatment-planning stage. Therefore, the field of radiogenomics has focused upon the identification of genetic variants associated with normal tissue toxicity resulting from radiotherapy. Innovative analytic methods are being applied to the discovery of risk variants and development of integrative predictive models that build on traditional normal tissue complication probability models by incorporating genetic information. Results from initial studies provide promising evidence that genetic-based risk models could play an important role in the implementation of precision medicine for radiation oncology through enhancing the ability to predict normal tissue reactions and thereby improve cancer treatment.

Original languageEnglish (US)
Pages (from-to)281-291
Number of pages11
JournalSeminars in Radiation Oncology
Volume25
Issue number4
DOIs
StatePublished - Oct 1 2015

Fingerprint

Single Nucleotide Polymorphism
Radiotherapy
Radiation
Therapeutics
Neoplasms
Precision Medicine
Radiation Oncology
Genetic Models
Comorbidity
Quality of Life
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Kerns, S. L., Kundu, S., Oh, J. H., Singhal, S. K., Janelsins, M., Travis, L. B., ... Rosenstein, B. S. (2015). The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention. Seminars in Radiation Oncology, 25(4), 281-291. https://doi.org/10.1016/j.semradonc.2015.05.006

The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models : A Step Toward Prevention. / Kerns, Sarah L.; Kundu, Suman; Oh, Jung Hun; Singhal, Sandeep K.; Janelsins, Michelle; Travis, Lois B.; Deasy, Joseph O.; Janssens, A. Cecile J E; Ostrer, Harry; Parliament, Matthew; Usmani, Nawaid; Rosenstein, Barry S.

In: Seminars in Radiation Oncology, Vol. 25, No. 4, 01.10.2015, p. 281-291.

Research output: Contribution to journalArticle

Kerns, SL, Kundu, S, Oh, JH, Singhal, SK, Janelsins, M, Travis, LB, Deasy, JO, Janssens, ACJE, Ostrer, H, Parliament, M, Usmani, N & Rosenstein, BS 2015, 'The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention', Seminars in Radiation Oncology, vol. 25, no. 4, pp. 281-291. https://doi.org/10.1016/j.semradonc.2015.05.006
Kerns, Sarah L. ; Kundu, Suman ; Oh, Jung Hun ; Singhal, Sandeep K. ; Janelsins, Michelle ; Travis, Lois B. ; Deasy, Joseph O. ; Janssens, A. Cecile J E ; Ostrer, Harry ; Parliament, Matthew ; Usmani, Nawaid ; Rosenstein, Barry S. / The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models : A Step Toward Prevention. In: Seminars in Radiation Oncology. 2015 ; Vol. 25, No. 4. pp. 281-291.
@article{5bc249e1e4e34f64bdf582795de7316b,
title = "The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention",
abstract = "Radiotherapy is a mainstay of cancer treatment, used in either a curative or palliative manner to treat approximately 50{\%} of patients with cancer. Normal tissue toxicity limits the doses used in standard radiation therapy protocols and impedes improvements in radiotherapy efficacy. Damage to surrounding normal tissues can produce reactions ranging from bothersome symptoms that negatively affect quality of life to severe life-threatening complications. Improved ways of predicting, before treatment, the risk for development of normal tissue toxicity may allow for more personalized treatment and reduce the incidence and severity of late effects. There is increasing recognition that the cause of normal tissue toxicity is multifactorial and includes genetic factors in addition to radiation dose and volume of exposure, underlying comorbidities, age, concomitant chemotherapy or hormonal therapy, and use of other medications. An understanding of the specific genetic risk factors for normal tissue response to radiation has the potential to enhance our ability to predict adverse outcomes at the treatment-planning stage. Therefore, the field of radiogenomics has focused upon the identification of genetic variants associated with normal tissue toxicity resulting from radiotherapy. Innovative analytic methods are being applied to the discovery of risk variants and development of integrative predictive models that build on traditional normal tissue complication probability models by incorporating genetic information. Results from initial studies provide promising evidence that genetic-based risk models could play an important role in the implementation of precision medicine for radiation oncology through enhancing the ability to predict normal tissue reactions and thereby improve cancer treatment.",
author = "Kerns, {Sarah L.} and Suman Kundu and Oh, {Jung Hun} and Singhal, {Sandeep K.} and Michelle Janelsins and Travis, {Lois B.} and Deasy, {Joseph O.} and Janssens, {A. Cecile J E} and Harry Ostrer and Matthew Parliament and Nawaid Usmani and Rosenstein, {Barry S.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.semradonc.2015.05.006",
language = "English (US)",
volume = "25",
pages = "281--291",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models

T2 - A Step Toward Prevention

AU - Kerns, Sarah L.

AU - Kundu, Suman

AU - Oh, Jung Hun

AU - Singhal, Sandeep K.

AU - Janelsins, Michelle

AU - Travis, Lois B.

AU - Deasy, Joseph O.

AU - Janssens, A. Cecile J E

AU - Ostrer, Harry

AU - Parliament, Matthew

AU - Usmani, Nawaid

AU - Rosenstein, Barry S.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Radiotherapy is a mainstay of cancer treatment, used in either a curative or palliative manner to treat approximately 50% of patients with cancer. Normal tissue toxicity limits the doses used in standard radiation therapy protocols and impedes improvements in radiotherapy efficacy. Damage to surrounding normal tissues can produce reactions ranging from bothersome symptoms that negatively affect quality of life to severe life-threatening complications. Improved ways of predicting, before treatment, the risk for development of normal tissue toxicity may allow for more personalized treatment and reduce the incidence and severity of late effects. There is increasing recognition that the cause of normal tissue toxicity is multifactorial and includes genetic factors in addition to radiation dose and volume of exposure, underlying comorbidities, age, concomitant chemotherapy or hormonal therapy, and use of other medications. An understanding of the specific genetic risk factors for normal tissue response to radiation has the potential to enhance our ability to predict adverse outcomes at the treatment-planning stage. Therefore, the field of radiogenomics has focused upon the identification of genetic variants associated with normal tissue toxicity resulting from radiotherapy. Innovative analytic methods are being applied to the discovery of risk variants and development of integrative predictive models that build on traditional normal tissue complication probability models by incorporating genetic information. Results from initial studies provide promising evidence that genetic-based risk models could play an important role in the implementation of precision medicine for radiation oncology through enhancing the ability to predict normal tissue reactions and thereby improve cancer treatment.

AB - Radiotherapy is a mainstay of cancer treatment, used in either a curative or palliative manner to treat approximately 50% of patients with cancer. Normal tissue toxicity limits the doses used in standard radiation therapy protocols and impedes improvements in radiotherapy efficacy. Damage to surrounding normal tissues can produce reactions ranging from bothersome symptoms that negatively affect quality of life to severe life-threatening complications. Improved ways of predicting, before treatment, the risk for development of normal tissue toxicity may allow for more personalized treatment and reduce the incidence and severity of late effects. There is increasing recognition that the cause of normal tissue toxicity is multifactorial and includes genetic factors in addition to radiation dose and volume of exposure, underlying comorbidities, age, concomitant chemotherapy or hormonal therapy, and use of other medications. An understanding of the specific genetic risk factors for normal tissue response to radiation has the potential to enhance our ability to predict adverse outcomes at the treatment-planning stage. Therefore, the field of radiogenomics has focused upon the identification of genetic variants associated with normal tissue toxicity resulting from radiotherapy. Innovative analytic methods are being applied to the discovery of risk variants and development of integrative predictive models that build on traditional normal tissue complication probability models by incorporating genetic information. Results from initial studies provide promising evidence that genetic-based risk models could play an important role in the implementation of precision medicine for radiation oncology through enhancing the ability to predict normal tissue reactions and thereby improve cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84941554669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941554669&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2015.05.006

DO - 10.1016/j.semradonc.2015.05.006

M3 - Article

C2 - 26384276

AN - SCOPUS:84941554669

VL - 25

SP - 281

EP - 291

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 4

ER -